Omeros Q3 sales of Yartemlea rise 26% as CHMP upholds negative opinion on narsoplimab
Omeros reported $35.9M in net revenue for its stem cell transplant TMA drug, while the EMA's CHMP kept its negative opinion on the EU application after re-examination.
Omeros Corp reported third-quarter 2026 results on 16 November, citing net revenue of $35.9M for Yartemlea (narsoplimab-wuug), up 26%. The product is approved in the US for transplant-associated thrombotic microangiopathy (TMA) following stem cell transplantation.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Omeros Corp ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.